Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 2/20 | 0.46 |
| ▸ | ARG2 | P78540 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
| ▸ | PNP | P00491 | 1/20 | 0.38 |
| ▸ | HTR1D | P28221 | 1/20 | 0.37 |
| ▸ | HTR1B | P28222 | 1/20 | 0.37 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.36 |
| ▸ | VEGFA | P15692 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2826704 | 1.00 | ARG1 (0.46) | ARG1ARG2DRD2HTR2AHTR2C | |
| SCHEMBL10064193 | 1.00 | ARG1 (0.46) | ARG1ARG2DRD2HTR2AHTR2C | |
| Formic Acid SCHEMBL27975005 | 0.91 | ARG1 (0.46) | ARG1ARG2DRD2HTR2AHTR2C | |
| SCHEMBL12280378 | 0.89 | ARG1 (0.47) | ARG1ARG2DRD2HTR2AHTR2C | |
| SCHEMBL7309716 | 0.89 | ARG1 (0.47) | ARG1ARG2DRD2HTR2AHTR2C | |
| SCHEMBL7309724 | 0.89 | ARG1 (0.47) | ARG1ARG2DRD2HTR2AHTR2C | |
| SCHEMBL855183 | 0.88 | ARG1 (0.46) | ARG1ARG2DRD2HTR2AHTR2C | |
| SCHEMBL2826721 | 0.86 | ARG1 (0.45) | ARG1ARG2DRD2HTR2AHTR2C | |
| SCHEMBL24917581 | 0.85 | DRD2 (0.46) | ARG1ARG2DRD2HTR2AHTR2C | |
| SCHEMBL25540921 | 0.85 | DRD2 (0.46) | ARG1ARG2DRD2HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023007009-A1 | PYRAZOLOPYRIMIDINES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2023-02-02 | — | — | WO | disclosed |
| US-9751876-B2 | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension | NOVARTIS AG (CH) | 2017-09-05 | — | — | US | disclosed |
| EP-2751108-B1 | BICYCLIC HETEROCYCLE DERIVATIVES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | NOVARTIS AG (CH) | 2016-04-27 | — | — | EP | disclosed |
| US-20150025059-A1 | BICYCLIC HETEROCYCLE DERIVATIVES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | NOVARTIS AG (CH) | 2015-01-22 | — | — | US | disclosed |
| US-8883819-B2 | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension | IRM LLC (BM) | 2014-11-11 | — | — | US | disclosed |
| EP-2751108-A1 | BICYCLIC HETEROCYCLE DERIVATIVES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | Novartis AG (CH) | 2014-07-09 | — | — | EP | disclosed |
| US-20130237519-A1 | BICYCLIC HETEROCYCLE DERIVATIVES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2013-09-12 | — | — | US | disclosed |
| WO-2013030802-A1 | BICYCLIC HETEROCYCLE DERIVATIVES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | NOVARTIS AG (CH) | 2013-03-07 | — | — | WO | disclosed |
| EP-2394998-A1 | 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors | Almirall, S.A. (ES) | 2011-12-14 | — | — | EP | disclosed |
| WO-2010069504-A1 | (3-OXO)PYRIDIN-4-YLUREA DERIVATIVES AS PDE4 INHIBITORS | ALMIRALL, S.A. (ES) | 2010-06-24 | — | — | WO | disclosed |
| EP-2196465-A1 | (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors | Almirall, S.A. (ES) | 2010-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237519-A1 | BICYCLIC HETEROCYCLE DERIVATIVES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | PDGFA, PDGFRA, PDGFRB | ARG1 25/4885ARG2 45/4885DRD2 3637/4885 |
| US-20150025059-A1 | BICYCLIC HETEROCYCLE DERIVATIVES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | PDGFA, PDGFRA, PDGFRB | ARG1 25/4885ARG2 45/4885DRD2 3637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.